$46m · Series B · Healthtech · Glasgow, UK
Glasgow-based Mironid, a biopharmaceutical company developing small-molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), has raised $46m in Series B financing. New investor the Scottish National Investment Bank joined Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures and the University of Strathclyde. The company said the capital would advance clinical development of its lead LoAc small molecule for ADPKD.
The Scottish National Investment Bank said its £8.4m equity commitment formed part of the same £34m round. The sterling figure is a reported equivalent of the company’s $46m announcement, not a separate financing.
The round funds the first human test
ADPKD is an inherited disorder in which fluid-filled cysts grow in the kidneys. Mironid’s LoAc programme is designed to reduce abnormally high levels of cyclic AMP, or cAMP, a signalling molecule that the company says drives both cyst formation and growth. Mironid reported that its preclinical studies reduced cyst number and kidney volume and showed a favourable safety profile, but those results remain company-reported preclinical evidence rather than proof of benefit in patients.
For a drug developer at this stage, the commercial value of a large Series B is concentrated in a narrow de-risking step: converting laboratory evidence into human safety, tolerability and pharmacokinetic data. That evidence can determine whether Mironid has a credible path into patient studies and can support future financing or partnership discussions. The capital is therefore buying a clinical readout, not commercial scale.
The round also combines continuity from specialist existing investors with a new public development-bank investor. The Bank framed its investment as support for translating Scottish research into clinical progress, while Mironid traces its origins to work at the University of Strathclyde and Heriot-Watt University. The syndicate’s next test is whether that scientific continuity produces usable human data.
On 1 October, Mironid said it had dosed the initial cohorts in a Phase 1 dose-escalation study in healthy volunteers, marking its move into clinical-stage development. The single-ascending-dose portion is designed to enrol up to 48 participants across six cohorts, with the company expecting initial data in the coming year. Starting the study is a tangible use-of-funds milestone; it does not yet establish safety or efficacy in people with ADPKD.
Sources checked:
Mironid funding announcement · Scottish National Investment Bank announcement · Mironid Phase 1 update · Mironid contact page · Tech.eu Funding Explorer
Image: Scottish National Investment Bank, via the official funding announcement.
